Early MRD Status After CAR-T Administration Predicted PFS, OS
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
CAR-T Therapy
Nonrelapse Mortality After CAR-T Therapy Remains High
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
The Untold Story of the Longest Persisting CAR-T Cells in CLL
A deep dive into how CAR-T cells evolved in 2 patients with chronic lymphocytic leukemia who have had the longest complete remissions to date.
BCMA CAR-T bb2121 Appears to Be Safe and Effective in Multiple Myeloma
An anti-BCMA CAR-T therapy appeared to be safe and effective for patients with relapsed or refractory multiple myeloma.
Remodeled CD19 CAR Shows Clinical Benefit, Low Toxicity in B-Cell Lymphoma
A second-generation anti-CD19 chimeric antigen receptor T-cell therapy showed clinical benefit and low toxicity in a phase 1 trial for B-cell lymphoma.
Resistance to CAR-T in B-Cell ALL Discussed at ASGCT Meeting
New possible mechanisms of resistance to CD19 CAR-T were put forth for B-cell acute lymphoblastic leukemia.
“Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
CAR-T in Multiple Myeloma: Promising Efficacy and Generally Manageable Toxicity
Interestingly, a number of patients ultimately achieving a sustained complete response initially experienced a partial response to this CAR T-cell therapy.
Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes
How one facility ensures compliance with a complex treatment protocol.
AFP SPEAR T Cells Deemed Safe in First 2 Treated Patients With Hepatocellular Carcinoma
This first-in-human trial will enroll up to 24 patients.
Next post in Gastrointestinal Cancers
